The “North and South America Renewable Energy Policy Handbook 2025” provides a comprehensive overview of the renewable energy policies across nine major countries in the Americas, including the United States, Canada, Brazil, and Mexico. The report highlights how policy measures and incentives are shaping the renewable energy landscape, addressing the impact of the US tariff which is expected to slow down renewable energy development. Furthermore, it discusses the OBBB’s influence on renewable energy dynamics in the U.S. and examines technological supports, renewable energy targets, and plans that are pivotal for strategic decisions and opportunities in the renewable energy sector throughout the region.

• Brookfield Asset Management last closed at CA$73.13 up 1%.

• NextEra Energy last closed at $85.54 up 0.8%, hovering around its 52-week high.

• Enbridge last closed at CA$67.47 up 0.6%, near its 52-week high.

In other trading, Fermi was a notable mover up 12.1% and finishing the session at $15.81. In the meantime, Shanghai Electric Power lagged, down 5% to end trading at CN¥22.80.

Enbridge offers a strong potential for stable returns through strategic asset expansions and inflation-protected revenue. Click to explore the full narrative on Enbridge’s investment opportunities and risks.

As a follow-up, review our Market Insights article “Rare Earths: Tiny Market, Outsized Influence,” to understand how rare earths shape strategic leverage in the energy transition, especially as geopolitical dynamics intensify and stock opportunities emerge. Act fast to grasp these evolving trends.

• Tesla finished trading at $426.58 up 1.7%.

• Chevron closed at $149.51 up 0.7%.

• Equinor ended the day at NOK231.10 up 0.6%, hovering around its 52-week low. This week, Jarle Roth was elected to the board of directors, effective December 1, 2025, at the company.

• Discover the full array of 188 Energy Transition Stocks, featuring Primoris Services, E.ON and Ormat Technologies, right here.

• Interested In Other Possibilities? AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part – they are all under $10b in market cap – there’s still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.